Skip to content
Themes / Specialty Chemicals & Pharma Intermediates
Parent theme

Specialty Chemicals & Pharma Intermediates

China+1 offshoring + deep chemical expertise + ESG compliance

china-plus-oneexportoligopolyparent-theme
Theme price path

Specialty Chemicals & Pharma Intermediates vs Nifty 500

Weekly basket performance over the latest 52 observations. Green is ahead of Nifty 500; red is behind.

Through 21 Oct 2026
Coverage healthy
Theme aheadTheme behindNifty 500Base 100 at the first visible weekLatest: Underperforming -7.2%
7683909710431 Oct 2025 | Specialty Chemicals & Pharma Intermediates 100.0 | Nifty 500 100.0 | In line 0.0% | breadth 33% | coverage 86%07 Nov 2025 | Specialty Chemicals & Pharma Intermediates 98.4 | Nifty 500 99.2 | Underperforming -0.8% | breadth 17% | coverage 86%14 Nov 2025 | Specialty Chemicals & Pharma Intermediates 97.0 | Nifty 500 100.5 | Underperforming -3.5% | breadth 25% | coverage 86%21 Nov 2025 | Specialty Chemicals & Pharma Intermediates 94.7 | Nifty 500 100.3 | Underperforming -5.6% | breadth 8% | coverage 86%28 Nov 2025 | Specialty Chemicals & Pharma Intermediates 94.6 | Nifty 500 100.9 | Underperforming -6.2% | breadth 42% | coverage 86%05 Dec 2025 | Specialty Chemicals & Pharma Intermediates 93.4 | Nifty 500 100.5 | Underperforming -7.1% | breadth 25% | coverage 86%12 Dec 2025 | Specialty Chemicals & Pharma Intermediates 93.2 | Nifty 500 100.1 | Underperforming -6.9% | breadth 42% | coverage 86%19 Dec 2025 | Specialty Chemicals & Pharma Intermediates 93.0 | Nifty 500 99.9 | Underperforming -6.9% | breadth 50% | coverage 86%26 Dec 2025 | Specialty Chemicals & Pharma Intermediates 93.1 | Nifty 500 100.3 | Underperforming -7.2% | breadth 58% | coverage 86%02 Jan 2026 | Specialty Chemicals & Pharma Intermediates 93.7 | Nifty 500 101.6 | Underperforming -7.8% | breadth 75% | coverage 86%09 Jan 2026 | Specialty Chemicals & Pharma Intermediates 91.0 | Nifty 500 99.0 | Underperforming -8.1% | breadth 17% | coverage 86%16 Jan 2026 | Specialty Chemicals & Pharma Intermediates 91.9 | Nifty 500 99.1 | Underperforming -7.3% | breadth 58% | coverage 86%23 Jan 2026 | Specialty Chemicals & Pharma Intermediates 85.6 | Nifty 500 95.8 | Underperforming -10.6% | breadth 0% | coverage 86%01 Feb 2026 | Specialty Chemicals & Pharma Intermediates 85.9 | Nifty 500 95.4 | Underperforming -10.0% | breadth 67% | coverage 86%06 Feb 2026 | Specialty Chemicals & Pharma Intermediates 87.4 | Nifty 500 98.8 | Underperforming -11.5% | breadth 58% | coverage 86%13 Feb 2026 | Specialty Chemicals & Pharma Intermediates 86.7 | Nifty 500 98.3 | Underperforming -11.8% | breadth 33% | coverage 86%20 Feb 2026 | Specialty Chemicals & Pharma Intermediates 86.5 | Nifty 500 98.7 | Underperforming -12.4% | breadth 50% | coverage 86%27 Feb 2026 | Specialty Chemicals & Pharma Intermediates 85.2 | Nifty 500 97.7 | Underperforming -12.8% | breadth 25% | coverage 86%06 Mar 2026 | Specialty Chemicals & Pharma Intermediates 83.0 | Nifty 500 94.8 | Underperforming -12.4% | breadth 25% | coverage 86%13 Mar 2026 | Specialty Chemicals & Pharma Intermediates 79.3 | Nifty 500 90.2 | Underperforming -12.1% | breadth 8% | coverage 86%20 Mar 2026 | Specialty Chemicals & Pharma Intermediates 79.7 | Nifty 500 90.0 | Underperforming -11.4% | breadth 58% | coverage 86%27 Mar 2026 | Specialty Chemicals & Pharma Intermediates 78.8 | Nifty 500 88.7 | Underperforming -11.2% | breadth 42% | coverage 86%02 Apr 2026 | Specialty Chemicals & Pharma Intermediates 78.0 | Nifty 500 88.3 | Underperforming -11.7% | breadth 33% | coverage 86%10 Apr 2026 | Specialty Chemicals & Pharma Intermediates 81.4 | Nifty 500 94.2 | Underperforming -13.6% | breadth 92% | coverage 86%17 Apr 2026 | Specialty Chemicals & Pharma Intermediates 84.5 | Nifty 500 96.5 | Underperforming -12.4% | breadth 100% | coverage 86%24 Apr 2026 | Specialty Chemicals & Pharma Intermediates 85.6 | Nifty 500 95.2 | Underperforming -10.1% | breadth 50% | coverage 86%30 Apr 2026 | Specialty Chemicals & Pharma Intermediates 87.5 | Nifty 500 95.7 | Underperforming -8.6% | breadth 67% | coverage 86%08 May 2026 | Specialty Chemicals & Pharma Intermediates 93.3 | Nifty 500 97.5 | Underperforming -4.3% | breadth 92% | coverage 86%15 May 2026 | Specialty Chemicals & Pharma Intermediates 91.6 | Nifty 500 95.0 | Underperforming -3.6% | breadth 33% | coverage 86%22 May 2026 | Specialty Chemicals & Pharma Intermediates 93.1 | Nifty 500 95.5 | Underperforming -2.5% | breadth 67% | coverage 86%29 May 2026 | Specialty Chemicals & Pharma Intermediates 91.8 | Nifty 500 95.6 | Underperforming -4.0% | breadth 25% | coverage 86%05 Jun 2026 | Specialty Chemicals & Pharma Intermediates 91.2 | Nifty 500 94.8 | Underperforming -3.8% | breadth 25% | coverage 86%12 Jun 2026 | Specialty Chemicals & Pharma Intermediates 93.1 | Nifty 500 95.3 | Underperforming -2.3% | breadth 75% | coverage 86%19 Jun 2026 | Specialty Chemicals & Pharma Intermediates 93.4 | Nifty 500 97.7 | Underperforming -4.4% | breadth 58% | coverage 86%26 Jun 2026 | Specialty Chemicals & Pharma Intermediates 92.2 | Nifty 500 97.5 | Underperforming -5.4% | breadth 42% | coverage 86%03 Jul 2026 | Specialty Chemicals & Pharma Intermediates 93.9 | Nifty 500 98.3 | Underperforming -4.5% | breadth 67% | coverage 86%10 Jul 2026 | Specialty Chemicals & Pharma Intermediates 94.7 | Nifty 500 98.5 | Underperforming -3.9% | breadth 58% | coverage 86%17 Jul 2026 | Specialty Chemicals & Pharma Intermediates 95.4 | Nifty 500 98.4 | Underperforming -3.0% | breadth 58% | coverage 86%24 Jul 2026 | Specialty Chemicals & Pharma Intermediates 93.9 | Nifty 500 96.7 | Underperforming -2.9% | breadth 33% | coverage 86%31 Jul 2026 | Specialty Chemicals & Pharma Intermediates 93.8 | Nifty 500 98.9 | Underperforming -5.2% | breadth 42% | coverage 86%07 Aug 2026 | Specialty Chemicals & Pharma Intermediates 96.2 | Nifty 500 100.0 | Underperforming -3.8% | breadth 75% | coverage 86%14 Aug 2026 | Specialty Chemicals & Pharma Intermediates 97.0 | Nifty 500 99.5 | Underperforming -2.5% | breadth 50% | coverage 86%21 Aug 2026 | Specialty Chemicals & Pharma Intermediates 97.0 | Nifty 500 99.1 | Underperforming -2.1% | breadth 50% | coverage 86%28 Aug 2026 | Specialty Chemicals & Pharma Intermediates 98.0 | Nifty 500 99.2 | Underperforming -1.2% | breadth 50% | coverage 86%04 Sept 2026 | Specialty Chemicals & Pharma Intermediates 96.4 | Nifty 500 98.1 | Underperforming -1.7% | breadth 25% | coverage 86%11 Sept 2026 | Specialty Chemicals & Pharma Intermediates 94.4 | Nifty 500 96.4 | Underperforming -2.1% | breadth 25% | coverage 86%18 Sept 2026 | Specialty Chemicals & Pharma Intermediates 93.4 | Nifty 500 96.3 | Underperforming -3.0% | breadth 42% | coverage 86%25 Sept 2026 | Specialty Chemicals & Pharma Intermediates 93.6 | Nifty 500 95.3 | Underperforming -1.8% | breadth 58% | coverage 86%01 Oct 2026 | Specialty Chemicals & Pharma Intermediates 89.2 | Nifty 500 92.2 | Underperforming -3.3% | breadth 8% | coverage 86%09 Oct 2026 | Specialty Chemicals & Pharma Intermediates 89.3 | Nifty 500 92.2 | Underperforming -3.1% | breadth 50% | coverage 86%16 Oct 2026 | Specialty Chemicals & Pharma Intermediates 89.1 | Nifty 500 93.9 | Underperforming -5.1% | breadth 50% | coverage 86%21 Oct 2026 | Specialty Chemicals & Pharma Intermediates 85.5 | Nifty 500 92.1 | Underperforming -7.2% | breadth 8% | coverage 86%Underperforming -7.2%31 Oct 202524 Apr 202621 Oct 2026
Theme return
-14.5%
Nifty 500
-7.9%
Vs Nifty 500
-7.2%
Latest coverage
12/14
How this plot is calculated

The theme line is green when its cumulative rebased performance is above Nifty 500 and red when it is below. The chart callout shows the latest relative performance as the theme level divided by the benchmark level, minus one.

The basket uses the theme's current reviewed companies. For each available week, we calculate every valid constituent's close-to-close return and give each company the same weight. If a weekly rollup is missing or lags the daily series, the final available daily close in that week is used.

For baskets with at least 10 valid stocks, the highest and lowest 5% of weekly returns are trimmed to reduce split, corporate-action, and single-stock distortions. Weekly basket returns are then compounded and rebased to 100 beside the Nifty 500.

Breadth is the share of valid constituents that rose that week. Coverage is the number with usable aligned prices divided by current membership. Weekly moves above 80% are excluded as likely data or corporate-action outliers.

Limitation: this is a current-membership historical reconstruction, not a point-in-time investable index. It can contain survivorship bias and excludes costs, liquidity impact, dividends, and rebalancing turnover.

Model note: Current-member weekly equal-weight returns (5% tails trimmed for baskets of 10+), compounded and rebased to 100 against Nifty 500; lagging weekly rollups are patched with the final available daily close, and rotation uses 13-week excess return with four-week acceleration.

Theme scorecard

Measures whether this idea is investable today by blending cohort quality, valuation cushion, and price momentum. It is a research filter, not advice.

Build portfolio from this theme
Theme
24
Stretched
Quality
10
Valuation
28
Momentum
51
Positive MoS
21%
P/E 45.9 · ROCE 16%
Curated research view

Specialty Chemicals

A focused investor view: high-conviction names first, then small/micro exposure only as controlled satellite risk. Live U-Score and MoS still come from the current database.

59/100
Theme score
Moderate
Investability
38.1
Live avg U
-225.4%
Live avg MoS

Curated company map

Names from the curated theme note. Solid chips are present in the live eligible cohort; dashed chips need membership review, ticker verification, or may be indirect/unlisted exposure.

4/10 live eligible
SRFAARTIINDPIINDVINATIORGADEEPAKNTRNAVINFLUORATULCLEANROSSARIFCL

Investment thesis

China+1, agrochemical demand, pharma intermediates, fluorochemicals, and export contracts support specialty chemicals, but the cycle has been uneven.

1-2 year outlook: Gradual recovery. Prefer balance-sheet strength and proven chemistry moats.
Recommended allocation: 5-8%.

Key triggers

  • Capacity stabilisation
  • Export recovery
  • China supply discipline
  • Specialty molecule demand

Major risks

  • China price competition
  • Raw-material volatility
  • Capex drag
  • Customer concentration
Small, micro, and SME names should be opt-in exposure. Suggested filters: U-Score above 65, positive MoS, Piotroski 7+, debt/equity below 0.8, promoter pledge below 10%, and enough traded value to exit without slippage.

Thesis

The Indian specialty chemical and pharma intermediates universe is transitioning from broad-based cyclical growth into a selective phase where deep chemical expertise, ESG compliance, and the China+1 offshoring trade determine winners. Global pharma and agrochemical innovators are qualifying Indian CDMOs as their first-alternative to Chinese suppliers; high-barrier fluorochemistry businesses are earning premium multiples; and amines / catalyst niches have genuine oligopoly structure. The cycle reality: FY24-25 saw destocking hit earnings, which is why many names still trade near 5-year lows despite the secular thesis being intact.

  • ▸Global buyers qualifying India as China-alternative (pharma + agrochem)
  • ▸High-barrier fluorochemistry oligopolies (EV battery + green H2 tailwinds)
  • ▸Post-destocking normalization expected through FY26
  • ▸Cohort split between pure-play niches and diversified compounders — choose by thesis

Sub-themes · pick a specific angle

Top picks across the cohort · ranked by U-Score within all sub-themes

Full cohort

SUMICHEMLarge
Sumitomo Chemical India Limited
Chemicals
WATCHLIST

Sumitomo Chemical India — strong local manufacturing + distribution

MoS: -72.8%Piotroski: 8/9ROCE: 22%P/E: 35.3D/E: 0.02
44
U-Score
₹384.10
Open →
SRFMid
SRF Limited
Chemicals
WATCHLIST

Strong R&D-driven fluorochem segment — >30% revenue + largest refrigerant maker

MoS: +3.8%Piotroski: 8/9ROCE: 15%P/E: 30.0D/E: 0.36
43
U-Score
₹2305.00
Open →
DIVISLABLarge
Divi's Laboratories Limited
Pharma
WATCHLIST

Largest API producer with deep custom synthesis capability

MoS: -485.3%Piotroski: 8/9ROCE: 22%P/E: 81.5D/E: 0.00
43
U-Score
₹9190.00
Open →
PIINDMid
PI Industries Limited
Chemicals
WATCHLIST

Dominant CDMO partner for innovators — high R&D intensity

MoS: +9.8%Piotroski: 8/9ROCE: 15%P/E: 30.7D/E: 0.03
38
U-Score
₹2103.00
Open →
FLUOROCHEMLarge
Gujarat Fluorochemicals Limited
Chemicals
WATCHLIST

Largest Indian PTFE manufacturer; PVDF capacity ramp for EV batteries

MoS: -79.7%Piotroski: 8/9ROCE: 10%P/E: 82.2D/E: 0.35
36
U-Score
₹4368.30
Open →
PPLPHARMASmall
Piramal Pharma Limited
Pharma
OVERVALUED

Significant high-potency API (HPAPI) and drug product capacity

MoS: -125.0%Piotroski: 8/9ROCE: 12%P/E: 34.0D/E: 0.10
30
U-Score
₹191.19
Open →
SYNGENESmall
Syngene International Limited
Pharma
OVERVALUED

Specialized science-as-a-service R&D and manufacturing CDMO

MoS: -1179.2%Piotroski: 7/9ROCE: 10%P/E: 52.7D/E: 0.09
29
U-Score
₹376.45
Open →
BALAMINESMicro
Balaji Amines Limited
Chemicals
OVERVALUED

Large producer of methylamines + specialty derivatives

MoS: -574.2%Piotroski: 7/9ROCE: 11%P/E: 30.5D/E: 0.07
25
U-Score
₹1924.40
Open →
ASTECSmall
Astec LifeSciences Limited
Industrials
OVERVALUED

CDMO partner for triazole fungicides + other intermediates

Piotroski: 0/9ROCE: -5%D/E: 1.15
8
U-Score
₹665.90
Open →
TANFACSmall
Tanfac Industries Ltd.
Industrials

Specialized fluorinated intermediates manufacturer

—
U-Score
₹14.20
Open →
SUVENPHARSmall
Suven Pharmaceuticals Ltd.
Pharma

Focused on complex CNS and oncology intermediates

—
U-Score
Open →
The rationale above is editorial — the ranking uses our U-Score engine so the names you see first are the strongest fundamentals fit, not the most popular or most-mentioned. Re-rank yourself if you weigh valuation or quality differently. All information is for study purposes only — consult your financial advisor before investing.